[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580144":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":23,"locations":29,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Edwards Lifesciences","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"EVOQUE treated",null,"Medicare patients with at least severe Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement with the EVOQUE device and is identified in the TVT Registry",[13],"Other: EVOQUE",{"label":15,"type":10,"description":16,"interventionNames":10},"EVOQUE eligible","Medicare eligible patients with severe, symptomatic Tricuspid Regurgitation that are identifiable in a commercial claims database linked with electronic health records.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"OTHER","EVOQUE","This is a retrospective, non-randomized study. The decision to intervene by TTVR with the EVOQUE device is made by the heart team.",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"TMTT GHER","CONTACT","949-250-3849","TMTT_GHER_EVIDENCE@edwards.com",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Irvine","California","92614","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-117.82311,33.66946,{"lat":41,"lon":40},[44],{"name":25,"role":26,"phone":10,"phoneExt":10,"email":28},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100580144","ttvr-strong-under-coverage-with-evidence-development-ced-study-100580144",false,"NCT06833476","TTVR STRONG Under Coverage With Evidence Development (CED) Study","Transcatheter Tricuspid Valve Replacement (TTVR) in Patients With Severe TR ONgoing Evidence Generation (STRONG) Under Coverage With Evidence Development (CED)","STRONG","Inclusion Criteria:\n\nMedicare eligible patients who have received an EVOQUE device or are EVOQUE eligible and have at least severe Tricuspid Regurgitation\n\nExclusion Criteria:\n\nCommercially insured patients who have received an EVOQUE device or are EVOQUE eligible or Medicare eligible patients with less than severe Tricuspid Regurgitation","ALL","65 Years",{"count":58,"type":59},2044,"ESTIMATED","OBSERVATIONAL","This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement procedure using the EVOQUE system.",[63],"Tricuspid Regurgitation",[20,65,66,67],"Coverage with Evidence Development","CED","TVT Registry","2025-03-27",{"date":70,"type":71},"2025-03-28","ACTUAL",{"date":73,"type":71},"2025-03-19",{"date":75,"type":59},"2032-12-31",{"name":5,"class":6},1]